Report: Sigma-Tau may sell a stake in company

Bloomberg cites sources close to Italy's Sigma-Tau who say that the company is considering selling a stake in the biotech following the death of its founder. Four Partners is advising the company, which is reportedly considering a deal that would value the company at $1.4 billion. Sigma-Tau has a pipeline of drugs in development for rare and neglected ailments. Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.